# Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas

> **NCT03071822** · PHASE4 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 50 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** cisplatin
- **DRUG:** ifosfamide
- **DRUG:** gemcitabine
- **DRUG:** L-asparaginase
- **DRUG:** etoposide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT03071822
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-24
- **Primary completion:** 2021-07-31
- **Final completion:** 2022-02-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03071822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03071822, "Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03071822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*